Lamivudine Generics (Lamivudine)

Lamivudine is a nucleoside analogue that is phosphorylated inside cells to its active triphosphate form. This active form competes with natural nucleosides for incorporation into viral DNA, causing premature chain termination and thereby inhibiting the reverse transcriptase of HIV and the polymerase of hepatitis B.

The specific dose of lamivudine is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions and local treatment guidelines.

Safety data for lamivudine in pregnancy and lactation are limited. The drug may be used during pregnancy only if the potential benefits justify any potential risk to the fetus, and breastfeeding decisions should be made in consultation with a healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lamivudine shares a similar mechanism with other nucleoside reverse transcriptase inhibitors such as emtricitabine and tenofovir. Compared with tenofovir, lamivudine generally has a lower risk of renal toxicity but may be less potent in some regimens. Choice of agent depends on resistance patterns, patient comorbidities and guideline recommendations.

Lamivudine should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Lamivudine is administered orally, usually as a tablet or capsule, and can be taken with or without food. Patients should swallow the dosage form whole with water and follow the prescriber’s schedule for dosing frequency.

Serious adverse events include lactic acidosis, severe hepatotoxicity, and pancreatitis. Patients should be instructed to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, severe fatigue, yellowing of the skin or eyes, or any signs of an allergic reaction.

Lamivudine should be avoided in individuals with known hypersensitivity to the drug or any of its components. Patients with severe renal impairment may require dose adjustment or alternative therapy, and those with active, uncontrolled hepatitis B flares should be evaluated carefully before initiation.